The Upheaval in Metastatic Hormone Sensitive Prostate Cancer (mHSPC) – Chris Sweeney & Mary-Ellen Taplin

Chris Sweeney, MD and Mary-Ellen Taplin, MD discuss their current approach to treating patients with metastatic hormone-sensitive prostate cancer (mHSPC). Dr. Sweeney first evaluates whether or not the patient is fit for chemotherapy and what their access is to abiraterone which both have a clear benefit in high volume disease. Based on the CHAARTED data, Dr. Taplin does not offer chemotherapy…

Read the full article here

Source: UroToday

Categories: Urology

Tags: mHSPC

Tweets with this article

UroToday.com

#mHSPC @ChrisSweens1 and Mary-Ellen Taplin, MD @DanaFarber discuss their approaches for treating patients with metastatic hormone sensitive prostate cancer and various trials in this setting with @CaPsurvivorship @NUFeinbergMed on UroToday. https://t.co/dQmFzajSu3 #ProstateCancer https://t.co/30bd3QeCaM

Initial Linguistic and Cultural Validation of the Satisfaction Survey for Inflatable Penile Implant (SSIPI) in Spanish – Beyond the Abstract

erectile dysfunction, inflatable penile prosthesis (IPP), Satisfaction Survey for Inflatable Penile Implant (SSIPI), better patient care for Spanish speaking individuals undergoing inflatable penile prosthesis surgery.

UroToday.com May 13, 2025

Optimizing Treatment in Metastatic Hormone-Sensitive Prostate Cancer: A Case Study Analysis – Alicia Morgans

Program: State-of-the-Art Interdisciplinary Management of Prostate Cancer This series is part of an Independent Medical Education Initiative Supported by BAYER U.S. LLC PHARMACEUTICALS Biographies: Alicia…

UroToday.com May 11, 2025

Landscape of Approved and Upcoming PSMA Imaging Agents “Presentation” – Amir Iravani

At the 2025 UCSF-UCLA PSMA Conference, Amir Iravani compares FDA-approved PSMA PET agents (gallium-68 PSMA-11, DCFPyL, rhPSMA-7.3) for prostate cancer imaging. Dr. Iravani notes similar…

UroToday.com May 11, 2025

The Use of Radioligand Treatments in Metastatic Castration-Resistant Prostate Cancer – Matthew Abramowitz

Program: State-of-the-Art Interdisciplinary Management of Prostate Cancer. This series is part of an Independent Medical Education Initiative Supported by BAYER U.S. LLC PHARMACEUTICALS Biographies: Matthew…

UroToday.com May 9, 2025

Real-World Evidence Informs Clinical Decision-Making in Metastatic Castration-Resistant Prostate Cancer – Alan Bryce

UroToday.com May 8, 2025

Case-Based Discussion on Navigating the Evolving Landscape of Castrate-Resistant Prostate Cancer Management – Oliver Sartor

UroToday.com May 7, 2025

ctDNA as a Prognostic Biomarker in Bladder Cancer Treatment Decisions – Nimira Alimohamed

Ashish Kamat speaks with Nimira Alimohamed about the evolution of circulating tumor DNA (ctDNA) in muscle invasive bladder cancer management. Dr. Alimohamed explains that current…

UroToday.com May 7, 2025

Avelumab’s Survival Impact in Diabetic vs Non-Diabetic Bladder Cancer Patients – Shilpa Gupta

Ashish Kamat speaks with Shilpa Gupta about the JAVELIN trial and its impact on bladder cancer treatment. Dr. Gupta discusses how this study established avelumab…

UroToday.com May 7, 2025

First Worldwide Correction of Ventral Peyronie’s Disease Utilizing Rigicon Inflatable Penile Prosthesis Combined with Plaque Incision & Grafting with Collagen Fleece (PICS-Technique) for Residual Curvature – Beyond the Abstract

Peyronie’s Disease, Ventral Peyronie’s Disease, Rigicon Inflatable Penile Prosthesis, Penile Prosthesis, Plaque Incision and Grafting with Collagen Fleece, (PICS-Technique, penile curvature after peyronies disease treatment,…

UroToday.com May 7, 2025

The Use of Imaging in Staging Localized Prostate Cancer: A Case Study on High-Risk Localized Prostate Cancer – Zachary Klaassen

UroToday.com May 6, 2025

Related Articles